HRT.so
Weight Loss Hormones
4.2 Rating
Subcutaneous injection (daily)

Liraglutide (Saxenda)

An established daily GLP-1 receptor agonist for weight management, producing moderate but consistent weight loss results.

Overview

Liraglutide (Saxenda) was the first GLP-1 receptor agonist approved specifically for chronic weight management. While producing less dramatic results than newer options, it has a longer track record and extensive safety data. It requires daily injections but remains an effective option for medical weight loss.

How It Works

Liraglutide activates GLP-1 receptors in the brain to increase satiety and reduce hunger. It slows gastric emptying and modulates the reward-related aspects of eating. These combined effects lead to reduced caloric intake and sustained weight loss.

Benefits

Established safety profile
Effective appetite suppression
Consistent moderate weight loss
Extensive clinical data
Improved metabolic markers
Reduced diabetes risk

Potential Side Effects

Nausea
Diarrhea
Constipation
Headache
Fatigue
Injection site reactions

Dosage Information

Started at 0.6mg daily, increased weekly by 0.6mg to the target dose of 3.0mg daily. Dose escalation typically takes 5 weeks.

Quick Facts

Administration

Subcutaneous injection (daily)

Rating

4.2 / 5.0

Category

Weight Loss Hormones

Common Symptoms

Obesity
Overweight with comorbidities
Appetite control issues
Moderate weight loss goals
Available Providers

JoinFridays

Starting at $117/month

9.68

Shed

10% off first month

9.64

TrimRx

Starting at $147/month

9.6
Compare All Providers

Common Questions

Find a Provider for Liraglutide (Saxenda)

Compare top providers offering this treatment.

Compare Providers